Jonathan Tang BSc. MSc. FIBMS

Over 17 years experience in the field of clinical chemistry and research into metabolic bone disease. Currently a HCPC registered advanced Biomedical Scientist in Biochemistry and a fellow member of the Institute of Biomedical Science (IBMS). Previously held position as a senior Biomedical Scientist of the liquid chromatography tandem mass spectrometry (LC-MS/MS) section at the Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool and Broadgreen University Hospital NHS Trust (2001-2011). Appointed senior research associate, Norwich Medical school, University of East Anglia (UEA) (2011-2016), then promoted to research fellow in metabolic bone disease since 2016.

In 2011, working closely with Prof. William (Bill) Fraser, established Bioanalytical facility (BAF); a multidisciplinary lab facility specialised in fully/semi-automated/manual HPLC-MS/MS, isotopic/non-isotopic immunoassay, and wet chemistry techniques. BAF is accredited by the Central Pathology Accreditation (CPA) and certified for Good Clinical Laboratory Practice (GCLP). I lead a team of research technicians, post-doctoral research associates, biomedical scientists and clinical scientists from UEA and the Norfolk and Norwich University Hospital NHS trust (NNUHFT). I also co-supervise MRes, PhD, BSc. and MBBS students.

I specialise in biochemical analysis of small molecules, proteins and peptides, used in diagnostics and clinical research studies in metabolic bone disease. My research focuses on vitamin D metabolites, bone remodelling/turnover biomarkers, osteoanabolics and homeostatic markers of calcium/phosphate metabolism. Key publications include development of LC-MS/MS assays for vitamin D metabolites (1,25-dihydrox vitamin D, 25-hydroxyvitamin D and 24, 25-dihydroxyvitamin D), and bone turnover markers in the study of their relationships in health and in disease, studies on the effects of vitamin D supplementation/exercise in sport athletes and in general populations. Currently hold grant funding from government, Pharma and research councils for studies in bone stress fracture and treatment using PTH therapeutics.


View graph of relations

ID: 29698